Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (1100)	6/16/2003 9:49:38 PM
From: Skywatcher	Read Replies (1) \| Respond to of 1137

With the current income situation and the SARS thing, as well as continued testing getting closer to proving the efficacy....I daresay they won't hit yet.....wish they'd go after ONXX so I could get some cheaper shares though. Not that they deserve it, but....neither did SCLN CC

To: JEB who wrote (1100)	6/27/2003 12:24:12 AM
From: Skywatcher	Read Replies (1) \| Respond to of 1137

SCICLONE PHARMACEUTICALS INC (SCLN) form 8-K Item 5. Other Events On June 25, 2003, SciClone Pharmaceuticals, Inc. issued a press release announcing positive data from its phase 3 hepatitis B trial in Japan. A copy of this press release is attached as Exhibit 99.1. In connection with this press release, we also held a conference call on June 25, 2003. During the conference call, the following disclosures were made: This ZADAXIN phase 3 Japanese hepatitis B trial was designed to demonstrate a clinical benefit, measured by a combination of efficacy and safety. The design of the trial did not have specific predetermined endpoints that are typical of clinical trials conducted in the United States. We believe that the overall safety and efficacy data will be the primary considerations in the Japanese Ministry of Health review process. The adefovir dipivoxil and lamivudine studies cited in our press release had different treatment regimes and endpoints from our Japanese trial. The sero-conversion rates of these two drugs were measured at the end of therapy whereas the sero-conversion rates reported in the ZADAXIN study were measured 12 months after the end of therapy. Although we have said that the drug review process in Japan typically requires 18 months or more from the date a Japanese New Drug Application (JNDA) is submitted, shareholders should not expect that this timing necessarily will apply to our Japanese trial. CC